Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback